Urogen Pharma's (URGN) "Buy" Rating Reaffirmed at D. Boral Capital

Key Points

• D. Boral Capital has reaffirmed a buy rating for Urogen Pharma, setting a price target of $25.00, which indicates a potential upside of 25.75% from the previous close.
• Urogen Pharma recently recorded a net loss of $0.92 earnings per share (EPS), falling short of analysts' estimates, with total revenue reported at $20.25 million.
• Insider sales were evident, with significant stock divestitures from executives, including a 3.15% decrease in ownership by Mark Schoenberg after selling over 5,149 shares.

D. Boral Capital restated their buy rating on shares of Urogen Pharma (NASDAQ:URGN - Free Report) in a research report sent to investors on Tuesday,Benzinga reports. D. Boral Capital currently has a $25.00 target price on the stock.

Several other equities research analysts also recently commented on the stock. The Goldman Sachs Group set a $16.00 target price on shares of Urogen Pharma and gave the company a "neutral" rating in a research note on Friday, June 13th. Oppenheimer set a $31.00 price objective on shares of Urogen Pharma and gave the stock a "buy" rating in a report on Friday, June 13th. Guggenheim reissued a "buy" rating and issued a $30.00 target price (up from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. HC Wainwright reiterated a "buy" rating and issued a $50.00 price objective on shares of Urogen Pharma in a research report on Tuesday, July 8th. Finally, Scotiabank restated an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Urogen Pharma currently has an average rating of "Buy" and an average target price of $32.86.

Urogen Pharma Stock Performance

NASDAQ:URGN opened at $20.01 on Tuesday. The company has a 50-day moving average of $13.17 and a 200-day moving average of $11.17. Urogen Pharma has a 52 week low of $3.42 and a 52 week high of $21.01. The company has a market capitalization of $924.46 million, a price-to-earnings ratio of -6.29 and a beta of 1.12.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The company had revenue of $20.25 million for the quarter, compared to analyst estimates of $22.71 million. Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%. Sell-side analysts forecast that Urogen Pharma will post -3.12 EPS for the current year.

Insider Activity

In other news, insider Mark Schoenberg sold 5,149 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $19.14, for a total value of $98,551.86. Following the transaction, the insider owned 158,229 shares of the company's stock, valued at $3,028,503.06. This represents a 3.15% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,522 shares of the company's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $19.14, for a total value of $143,971.08. Following the completion of the sale, the general counsel owned 41,492 shares of the company's stock, valued at $794,156.88. This represents a 15.35% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 17,833 shares of company stock valued at $280,567 over the last three months. Company insiders own 4.70% of the company's stock.

Institutional Trading of Urogen Pharma

A number of large investors have recently bought and sold shares of URGN. CWM LLC boosted its holdings in Urogen Pharma by 6,047.1% during the first quarter. CWM LLC now owns 5,225 shares of the company's stock worth $58,000 after purchasing an additional 5,140 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of Urogen Pharma in the 4th quarter valued at about $59,000. Lazard Asset Management LLC acquired a new stake in shares of Urogen Pharma in the fourth quarter valued at about $67,000. GAMMA Investing LLC raised its holdings in Urogen Pharma by 6,908.4% during the first quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock worth $83,000 after acquiring an additional 7,392 shares in the last quarter. Finally, Aquatic Capital Management LLC acquired a new position in Urogen Pharma during the fourth quarter valued at approximately $101,000. 91.29% of the stock is owned by institutional investors.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.